Regeneron Pharmaceuticals REGN Get Free Report has outperformed the market over the past 15 years by 12.37% on an annualized ...

NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...